Gómez Juan, Lorca Rebeca, Reguero Julian R, Morís César, Martín María, Tranche Salvador, Alonso Belén, Iglesias Sara, Alvarez Victoria, Díaz-Molina Beatriz, Avanzas Pablo, Coto Eliecer
From the Unidad de Referencia de Cardiopatías Familiares-HUCA, Genética Molecular y Cardiología, Hospital Universitario Central Asturias, Oviedo, Spain (J.G., R.L., J.R.R., C.M., M.M., B.A., S.I., V.A., B.D.-M., P.A., E.C.); Fundación Asturcor, Spain (J.R.R., C.M.); Departamento de Medicina, Universidad de Oviedo, Spain (C.M., E.C.); Centro Salud El Cristo, Oviedo, Spain (S.T.); and Red de Investigación Renal (REDINREN), Madrid, Spain (E.C.).
Circ Cardiovasc Genet. 2017 Apr;10(2). doi: 10.1161/CIRCGENETICS.116.001584.
Recent exome sequencing studies identified filamin C () as a candidate gene for hypertrophic cardiomyopathy (HCM). Our aim was to determine the rate of candidate variants in a large cohort of HCM patients who were also sequenced for the main sarcomere genes.
A total of 448 HCM patients were next generation-sequenced (semiconductor chip technology) for the , , , , , , , , and genes. We also sequenced 450 healthy controls from the same population. Based on the reported population frequencies, bioinformatic criteria, and familial segregation, we identified 20 candidate variants (13 new; 1 nonsense; and 19 missense) in 22 patients. Compared with the patients, only 1 of the control's missense variants was nonreported (=0.007; Fisher exact probability test). Based on the familial segregation and the reported functional studies, 6 of the candidate variants (in 7 patients) were finally classified as likely pathogenic, 10 as variants of uncertain significance, and 4 as likely benign.
We provide a compelling evidence of the involvement of in the development of HCM. Most of the variants were associated with mild forms of HCM and a reduced penetrance, with few affected in the families to confirm the segregation. Our work, together with others who found variants among patients with dilated and restrictive cardiomyopathies, pointed to this gene as an important cause of structural cardiomyopathies.
近期的外显子组测序研究确定细丝蛋白C(FLNC)为肥厚型心肌病(HCM)的候选基因。我们的目的是确定在一大群HCM患者中FLNC候选变异的发生率,这些患者同时也对主要肌节基因进行了测序。
对总共448例HCM患者进行了下一代测序(半导体芯片技术),检测FLNC、肌球蛋白重链7(MYH7)、肌钙蛋白T(TNNT2)、肌钙蛋白I(TNNI3)、肌球蛋白结合蛋白C(MYBPC3)、α-原肌球蛋白(TPM1)、肌联蛋白(TTN)、肌动蛋白(ACTN2)和肌球蛋白轻链3(MYL3)基因。我们还对来自同一人群的450名健康对照进行了测序。基于报道的人群频率、生物信息学标准和家系分离情况,我们在22例患者中鉴定出20个FLNC候选变异(13个新变异;1个无义变异;19个错义变异)。与患者相比,对照者中只有1个错义变异未被报道(P = 0.007;Fisher精确概率检验)。基于家系分离和报道的功能研究,最终将6个候选变异(在7例患者中)分类为可能致病,10个为意义未明的变异,4个为可能良性。
我们提供了令人信服的证据表明FLNC参与了HCM的发生发展。大多数FLNC变异与轻度HCM形式和降低的外显率相关,家族中受影响者很少以确认分离情况。我们的工作以及其他在扩张型和限制型心肌病患者中发现FLNC变异的研究,都指出该基因为结构性心肌病的一个重要病因。